Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients

Currently, no targeted therapies are available for metastatic triplenegative breast cancer (mTNBC). We evaluated the safety, efficacy, and biomarkers of response to cabozantinib, a multikinase inhibitor, in patients with mTNBC. We conducted a single arm phase II and biomarker study that enrolled pat...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncologist
Huvudupphovsmän: Tolaney, Sara M., Ziehr, David R., Guo, Hao, Ng, Mei R., Barry, William T., Higgins, Michaela J., Isakoff, Steven J., Brock, Jane E., Ivanova, Elena V., Paweletz, Cloud P., Demeo, Michelle K., Ramaiya, Nikhil H., Overmoyer, Beth A., Jain, Rakesh K., Winer, Eric P., Duda, Dan G.
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2017
Ämnen:
Breast Cancer
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5313267/
https://ncbi.nlm.nih.gov/pubmed/27789775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0229
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk